Shares of uniQure N.V. (NASDAQ: QURE) were suspended for a regulatory announcement and were expected to trade higher when markets reopened after the company disclosed that the U.S. Food and Drug Administration agreed the three-year follow-up data from its Phase I/II studies can be used as the primary foundation for a Biologics License Application (BLA) under the agency's accelerated approval pathway for AMT-130 in Huntington's disease.
In a recent Type B meeting, uniQure said the FDA confirmed the acceptability of the three-year analysis for a BLA submission. The company intends to submit that BLA in the third quarter of 2026. Separately, the regulator indicated it will work promptly with uniQure to reach alignment on the design of a confirmatory study prior to the filing.
The FDA sought alignment on several aspects of the confirmatory study design, including the potential use of a concurrent control arm receiving standard-of-care therapy rather than a sham surgical procedure. uniQure stated it is committed to initiating the confirmatory study without delay and expects to agree on study details with the agency before making the BLA submission.
AMT-130 has received multiple expedited development designations from the FDA: Regenerative Medicine Advanced Therapy (RMAT), Breakthrough Therapy, and Fast Track. According to uniQure, the RMAT designation was the first of its kind granted for Huntington's disease.
uniQure is conducting two multi-center, dose-escalating Phase I/II clinical trials to evaluate safety, tolerability, and exploratory efficacy signals for AMT-130. The U.S. trial enrolled 26 patients with early manifest Huntington's disease. Participants were randomized to receive either the investigational treatment or a sham procedure. Treated patients underwent a single administration of AMT-130 delivered directly into the striatum using MRI-guided stereotactic neurosurgical techniques.
The company said it expects to receive the final minutes from the Type B meeting within 30 days. Market activity surrounding the regulatory news prompted the trading halt, with uniQure shares set to resume trading following the disclosure.
Next steps and market context
uniQure plans to file the BLA in 3Q 2026 on the basis of the three-year Phase I/II data. Before filing, the company and the FDA will continue discussions to finalize the confirmatory study design, which may include a concurrent control on standard-of-care therapy rather than a sham surgery control. The firm has committed to advancing the confirmatory study without delay, and it expects formal meeting minutes within 30 days of the Type B discussion.
Regulatory recognitions
- AMT-130 holds RMAT, Breakthrough Therapy, and Fast Track designations from the FDA.
- The RMAT designation noted by the company was the first RMAT granted for Huntington's disease.
Clinical program
- Two multi-center, dose-escalating Phase I/II studies are underway to explore safety, tolerability, and exploratory efficacy.
- The U.S. study randomized 26 patients with early manifest Huntington's disease to treatment or sham, with treated patients receiving a single MRI-guided stereotactic neurosurgical administration of AMT-130 into the striatum.
Implications for investors and sectors
The announcement impacts uniQure equity and broader healthcare and biotech sectors, where regulatory milestones can lead to pronounced market reactions. The company reiterated a timeline for filing and a commitment to align with the FDA on confirmatory trial design prior to submission.